Evolución del abordaje terapéutico de la miopía en la Argentina: mapa terapéutico 2023

Rodolfo Aguirre; María Marta Galán; Abel Szeps; Leonardo Fernández Irigaray; Carlos Kotlik; Gabriela Rodríguez; Rafael Iribarren; Grupo de Estudio de Miopía de la Sociedad Argentina de Oftalmología Infantil (SAOI)

doi:10.70313/2718.7446.v17.n02.322

Authors

Rodolfo Aguirre Consultorio Oftalmológico Dr. Rodolfo Aguirre, Coronel Suárez, Buenos Aires, Argentina
María Marta Galán Hospital de Niños Sor María Ludovica, La Plata, Buenos Aires, Argentina
Abel Szeps Hospital Posadas, El Palomar, Buenos Aires, Argentina
Leonardo Fernández Irigaray Consultorio Oftalmológico Dr. Leonardo Fernández Irigaray, Buenos Aires, Argentina
Carlos Kotlik Hospital Notti, Mendoza, Mendoza, Argentina
Gabriela Rodríguez Consultorio Oftalmológico Dra. Gabriela Rodríguez, Buenos Aires, Argentina
Rafael Iribarren Consultorios Oftalmológicos Doctores Iribarren, Buenos Aires, Argentina. Fundación Retina, Buenos Aires, Argentina
Grupo de Estudio de Miopía de la Sociedad Argentina de Oftalmología Infantil (SAOI) Grupo de Estudio de Miopía de la Sociedad Argentina de Oftalmología Infantil (SAOI)

DOI:

https://doi.org/10.70313/2718.7446.v17.n02.322

Keywords:

myopia, therapeutic management, preferred practices, public health

Abstract

Objective: Considering that myopia has become a pandemic, this study aims to analyze the therapeutic approach to myopia in Argentina based on a survey conducted in 2023.

Methods: This is a cross-sectional study based on a survey developed by the Myopia Study Group of Argentina with questions disseminated from the networks of the Argentine Council of Ophthalmology (CAO). The questions were asked in order to obtain data from the professional practice in relation to the new treatments available by scientific evidence for the control of myopia progression in childhood.

Results: In 2023, 283 responses were obtained from a universe of more than 5000 ophthalmologists from the EAC. We detected that super dilute atropine was the most commonly used option by 79.7% of pediatric ophthalmologists, and 52.7% of general ophthalmologists. Recommendations to achieve at least 2hrs of daily outdoor exposure are used by 100% of pediatric ophthalmologists and 97.1% of general ophthalmologists. Decreasing the time of near activities was suggested by 100% of pediatric ophthalmologists and 42.8% of general ophthalmologists.

Conclusions: The therapeutic approach to myopia is close to consensus recommendations. We suggest from the Myopia Study Group to define programs to present the scientific evidence to the medical community, through different means of communication, in order to optimize the results for the prevention of myopia in the long term.

References

Morgan IG, Wu PC, Ostrin LA et al. IMI risk factors for myopia. Invest Ophthalmol Vis Sci 2021; 62: 3.

Wildsoet CF, Chia A, Cho P et al. IMI - Interventions Myopia Institute: interventions for controlling myopia onset and progression report. Invest Ophthalmol Vis Sci 2019; 60: M106-M131.

Wolffsohn JS, Kollbaum PS, Berntsen DA et al. IMI clinical myopia control trials and instrumentation report. Invest Ophthalmol Vis Sci 2019; 60: M132-M160.

He M, Xiang F, Zeng Y et al. Effect of time spent outdoors at school on the development of myopia among children in China: a randomized clinical trial. JAMA 2015; 314: 1142-1148.

He X, Sankaridurg P, Wang J et al. Time outdoors in reducing myopia: a school-based cluster randomized trial with objective monitoring of outdoor time and light intensity. Ophthalmology 2022; 129: 1245-1254.

Iribarren R Iribarren L. Myopia and culture: social, environmental and educational changes after Western colonization. J Clin Exp Ophthalmol 2022; 13: 1-9. Disponible en: https://www.longdom.org/open-access-pdfs/myopia-and-culture.pdf

Jonas JB, Ang M, Cho P et al. IMI prevention of myopia and its progression. Invest Ophthalmol Vis Sci 2021; 62: 6.

Holden BA, Fricke TR, Wilson DA et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology 2016; 123: 1036-1042.

Wolffsohn JS, Calossi A, Cho P et al. Global trends in myopia management attitudes and strategies in clinical practice: 2019 update. Cont Lens Anterior Eye 2020; 43: 9-17.

Wolffsohn JS, Calossi A, Cho P et al. Global trends in myopia management attitudes and strategies in clinical practice. Cont Lens Anterior Eye 2016; 39: 106-116.

Iribarren R, Cerrella MR, Armesto A et al. Age of lens use onset in a myopic sample of office-workers. Curr Eye Res 2004; 28: 175-180.

Galan MM SA, Fernandez Irigaray L, Rodriguez G, Aguirre R, Kotlik C, Iribarren R. Consensus on progressive myopia management. Oftalmol Clin Exp 2022; 15: e137-e156.

World Society of Paediatric Ophthalmology & Strabismus (WSPOS). Declaración de consenso sobre la miopía 2023. London: WSPOS, 2023. Disponible en: https://www.wspos.org/wp-content/uploads/2023/06/WSPOS-Myopia-Consensus-Statement-Spanish-Translation.pdf

Argentina. Instituto Nacional de Estadística y Censos (INDEC). Censo 2022. Buenos Aires: INDEC, 2023. Disponible en: https://censo.gob.ar/

Magnetto I, Magnetto O, Torres RM, Iribarren R. Low prevalence of myopia in children from a rural population in Marcos Juárez, Argentina. Oftalmol Clin Exp 2022; 15: e31-e39.

Iurescia A, Iribarren R, Lanca C, Grzybowski A. Accommodative-vergence disorders in a paediatric ophthalmology clinical setting in Argentina. Acta Ophthalmol 2024; 102: e346-e351.